Ant Venom-Based Ceramide Therapy Is Effective Against Atopic Dermatitis In Vivo.

Abstract

BACKGROUND:

Atopic dermatitis (AD) is a common skin condition with relatively few therapeutic alternatives. These include corticosteroids, which address inflammation but not superinfection, and Januse kinase (JAK) inhibitors, which have a US Food and Drug Administration (FDA) black box for potential carcinogenicity.

METHODS:

We demonstrate that S14, a synthetic derivative of ant venom-derived solenopsin, has potent anti inflammatory effects on the OVA murine model of atopic dermatitis. S14 has demonstrated prior activity in murine psoriasis and has the benefit of ceramide anti-inflammatory effects without being able to be metabolized into proinflammatory sphingosine-1 phosphate.

RESULTS:

The efficacy of S14 accompanied by the induction of IL-12 suggests a commonality in inflammatory skin disorders, and our results suggest that pharmacological ceramide restoration will be broadly effective for inflammatory skin disease.

CONCLUSIONS:

Solenopsin derivative S14 has anti-inflammatory effects in murine models of AD and psoriasis. This makes S14 a strong candidate for human use, and pre-IND studies are warranted.J Drugs Dermatol. 2023;22(10):1001-1006 doi:10.36849/JDD.7308.

• Authors: Juan Manuel Leyva-Castillo, Christina Huang, Paola Baker, John Bacsa, Raif S Geha, Jack L Arbiser
• Journal: Journal of drugs in dermatology : JDD (J Drugs Dermatol) Vol. 22 Issue 10 Pg. 1001-1006 (Oct 01 2023) ISSN: 1545-9616 [Print] United States
• PMID: 37801525 (Publication Type: Journal Article)

Chemical References

• Ant Venoms
• Ceramides
• Anti-Inflammatory Agents

Topics

• Humans
• Mice
• Animals
• Dermatitis, Atopic (drug therapy)
• Ant Venoms (therapeutic use)
• Ceramides (therapeutic use)
• Psoriasis (drug therapy)
• Anti-Inflammatory Agents (therapeutic use)